SCHEMBL150609

SCHEMBL150609

NC(CC(=O)O)(CC(=O)O)C(N)(CC(=O)O)CC(=O)O.[NaH]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
HMGCR P04035 1/20 0.43
CHRM1 P11229 1/20 0.43
TBXA2R P21731 1/20 0.43
ADRA1A P35348 1/20 0.43
KDM4E B2RXH2 1/20 0.42
CYP2C19 P33261 2/20 0.41
HIF1A Q16665 2/20 0.41
TSHR P16473 2/20 0.41
CYP2D6 P10635 1/20 0.41
GLRA1 P23415 1/20 0.39
SLC6A9 P48067 1/20 0.39
OR51E2 Q9H255 1/20 0.39
CPT2 P23786 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
FFAR1 O14842 1/20 0.36
ACLY P53396 3/20 0.35
LDHA P00338 1/20 0.33
SRR Q9GZT4 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17102799 1.00 ALDH1A1 (0.43) ALDH1A1HMGCRCHRM1TBXA2RADRA1A
SCHEMBL444254 1.00 ALDH1A1 (0.43) ALDH1A1HMGCRCHRM1TBXA2RADRA1A
SCHEMBL1274984 1.00 ALDH1A1 (0.43) ALDH1A1HMGCRCHRM1TBXA2RADRA1A
SCHEMBL41577 1.00 ALDH1A1 (0.43) ALDH1A1HMGCRCHRM1TBXA2RADRA1A
Water SCHEMBL4943812 0.97 ALDH1A1 (0.41) ALDH1A1HMGCRCHRM1TBXA2RADRA1A
Water SCHEMBL7071971 0.97 ALDH1A1 (0.41) ALDH1A1HMGCRCHRM1TBXA2RADRA1A
SCHEMBL17215697 0.97 ALDH1A1 (0.41) ALDH1A1HMGCRCHRM1TBXA2RADRA1A
Water SCHEMBL2300544 0.97 ALDH1A1 (0.41) ALDH1A1HMGCRCHRM1TBXA2RADRA1A
Water SCHEMBL9621712 0.97 ALDH1A1 (0.41) ALDH1A1HMGCRCHRM1TBXA2RADRA1A
SCHEMBL4652123 0.97 ALDH1A1 (0.41) ALDH1A1HMGCRCHRM1TBXA2RADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099342-A1 ORAL CARE COMPOSITION FOR USE IN THE TREATMENT OF DRY MOUTH ORAL CARE SOLUTIONS GMBH (CH) 2026-05-15 WO claimed
EP-4740931-A1 ORAL CARE COMPOSITION FOR USE IN THE TREATMENT OF DRY MOUTH Oral Care Solutions GmbH (CH) 2026-05-13 EP claimed
US-20250367170-A1 TOPICAL ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) FOR TREATING EYE CONDITIONS CLEVELAND CLINIC FOUND (US) 2025-12-04 US claimed
US-12460192-B2 Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing SPECIFIC BIOLOGICS INC. (CA) 2025-11-04 US claimed
US-12459904-B2 Process for preparing carbamoyloxymethyl triazole cyclohexyl acid compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2025-11-04 US claimed
EP-4638677-A1 CONTACT LENS TREATING SOLUTION Bausch + Lomb Ireland Limited (IE) 2025-10-29 EP claimed
US-20250297238-A1 LIPID-ENCAPSULATED DUAL-CLEAVING ENDONUCLEASE FOR DNA AND GENE EDITING SPECIFIC BIOLOGICS INC. (CA) 2025-09-25 US claimed
EP-4532017-A1 TOPICAL ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) FOR TREATING EYE CONDITIONS The Cleveland Clinic Foundation (US) 2025-04-09 EP claimed
US-12163093-B2 Chelating agents for barium sulfate dissolution in displacment spacer systems BAKER HUGHES OILFIELD OPERATIONS LLC (US) 2024-12-10 US claimed
US-20240350402-A1 TOPICAL DRUG TREATMENT TO PREVENT OR REDUCE CORNEAL SCARRING THE CLEVELAND CLINIC FOUNDATION 2024-10-24 US claimed
EP-0350540-A1 Composition for the maintenance of cars BETA PICTORIS INC. (LR) 1990-01-17 EP claimed
US-4814439-A Chemical process for the denitration of nitrocellulose THE UNITED STATES OF AMERICA AS REPESENTED BY THE SECRETARY OF THE ARMY (US) 1989-03-21 US claimed
EP-0238551-A4 METHODS FOR THE RECOVERY OF TISSUE PLASMINOGEN ACTIVATOR. CODON (US) 1988-02-01 EP claimed
EP-0238551-A1 METHODS FOR THE RECOVERY OF TISSUE PLASMINOGEN ACTIVATOR BERLEX LABORATORIES, INC. (US) 1987-09-30 EP claimed
WO-1987001389-A1 METHODS FOR THE RECOVERY OF TISSUE PLASMINOGEN ACTIVATOR CODON (US) 1987-03-12 WO claimed
EP-0115077-B1 BLOOD DILUENT Becton Dickinson and Company (US) 1987-03-11 EP claimed
US-4200238-A Method of preparing a rapidly soluble and machine handleable particulate composite and product OWENS-ILLINOIS, INC. (US) 1980-04-29 US claimed
US-4124542-A AMMONIUM LAURYL SULFATE OUTRIGHT INDUSTRIES, INC., A CORP. OF NV. 1978-11-07 US claimed
US-3961087-A Process for preparing cooked rice AMERICAN FROZEN FOODS CORPORATION (US) 1976-06-01 US claimed
US-3941723-A Crystallized alkali metal silicate with sequestering agents PHILADELPHIA QUARTZ COMPANY (US) 1976-03-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459904-B2 Process for preparing carbamoyloxymethyl triazole cyclohexyl acid compounds LPAR2, LPAR3, LPAR5 ALDH1A1 3831/4885HMGCR 1892/4885CHRM1 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.